Micromet, Inc.
(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases, announced the start of a phase 1 clinical trial with its BiTE(R)
antibody MT110. The study will explore the safety, pharmacokinetics,
pharmacodynamics and anti-tumor activity of MT110 in patients with lung and
gastrointestinal cancers.


MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326),
which is highly expressed on colon, lung, breast, prostate, ovarian,
gastric and pancreas cancers. Additionally, EpCAM has been found on cancer
stem cells of colon, breast, prostate and pancreas cancers. Cancer stem
cells are believed to cause metastases and recurrence of these cancers.
MT110 is the second BiTE antibody in clinical trials, and the fourth
clinical program in Micromet's product pipeline. The first BiTE antibody,
MT103 (MEDI-538), is now in phase 1 and phase 2 clinical trials for the
treatment of haematological cancers.



"BiTE antibodies enable the patients' own T cells to very efficiently
eliminate tumor cells," comments Patrick Baeuerle, Chief Scientific Officer
of Micromet, "In various experimental tumor models, we have demonstrated
the high therapeutic potential of EpCAM-specific BiTE antibodies, and we
are now looking forward to determining the safety and the therapeutic
potential of MT110 in patients."



"Having obtained clinical proof of concept for our BiTE antibody
technology with MT103 in haematological cancers, we are excited about
exploring the potential of MT110 in treating solid tumors," comments
Carsten Reinhardt, Chief Medical Officer of Micromet. "Based on its unique
mode of action, MT110 may be suited to treat established tumors as well as
disseminated cancer cells, which frequently give rise to metastases."



About BiTE Antibodies



BiTE(R) antibodies are designed to direct the body's cytotoxic, or
cell-destroying, T cells against tumor cells, and represent a new
therapeutic approach to cancer therapy. BiTE antibodies have been shown to
induce an immunological synapse between a T cell and a tumor cell in the
same manner as observed during physiological T cell attacks. These
cytolytic synapses enable the delivery of cytotoxic proteins from T cells
into tumor cells, ultimately inducing a self-destruction process in the
tumor cell referred to as apoptosis, or programmed cell death. In the
presence of BiTE antibodies, T cells have been demonstrated to serially
eliminate tumor cells, which explains the activity of BiTE antibodies at
very low concentrations and at very low ratios of T cells to target cells.
Through the process of killing cancer cells, T cells proliferate, which
leads to an increased number of T cells at the site of attack.



Several antibodies in Micromet's product pipeline are BiTE antibodies
and have been generated based on Micromet's proprietary BiTE antibody
platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting
CD19, and has provided proof-of-concept in an ongoing phase 1 clinical
study in patients with advanced non-Hodgkin's lymphoma. MT110, which is
targeting EpCAM (CD326) and is the first BiTE antibody with potential
applications in the treatment of solid tumors, is in a phase 1 clinical
trial in patients with lung and gastrointestinal cancers. Two additional
BiTE antibodies, targeting CD33 and MCSP, are in preclinical development.



About Micromet, Inc.



Micromet, Inc. is a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation and
autoimmune diseases. Four of its antibodies are currently in clinical
trials, while the remainder of the product pipeline is in preclinical
development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for
the treatment of patients with acute lymphoblastic leukemia and in a phase
1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma.
BiTE antibodies represent a new class of antibodies that activate a
patient's own cytotoxic T cells, considered the most powerful "killer
cells" of the human immune system, to eliminate cancer cells. Micromet is
developing MT103 in collaboration with MedImmune, Inc., a subsidiary of
AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and
is being developed by Micromet in a phase 1 clinical trial for the
treatment of patients with lung and gastrointestinal cancer. The third
clinical stage antibody is adecatumumab, also known as MT201, a human
monoclonal antibody which targets epithelial cell adhesion molecule
(EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in
collaboration with Merck Serono in a phase 1b clinical trial evaluating
adecatumumab in combination with docetaxel for the treatment of patients
with metastatic breast cancer. The fourth clinical stage antibody is MT293
which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in
a phase 1 clinical trial for the treatment of patients with cancer. In
addition, Micromet has established a collaboration with Nycomed for the
development and commercialization of MT203, a human antibody neutralizing
the activity of granulocyte/macrophage colony stimulating factor (GM-CSF),
which has potential applications in the treatment of various inflammatory
and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or
multiple sclerosis.



Forward-Looking Statements



This release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause actual
results to differ materially from any future results expressed or implied
by any forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or clinical
trials do not demonstrate safety and/or efficacy in subsequent clinical
trials, the risk that encouraging results from early research, preclinical
studies or clinical trials may not be confirmed upon further analysis of
the detailed results of such research, preclinical study or clinical trial,
the risk that additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon further
analysis of preclinical or clinical trial data, the risk that we or our
collaborators will not obtain approval to market our product candidates,
the risks associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on collaborators,
including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities relating to
our product candidates. You are urged to consider statements that include
the words "ongoing," "may," "will," "would," "could," "should," "believes,"
"estimates," "projects," "potential," "expects," "suggests," "plans,"
"anticipates," "intends," "continues," "forecast," "designed," "goal," or
the negative of those words or other comparable words to be uncertain and
forward-looking. These factors and others are more fully discussed in our
periodic reports and other filings with the SEC.



Any forward-looking statements are made pursuant to Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and, as such, speak only as of the date
made. Micromet, Inc. undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
events or otherwise.


Micromet, Inc.

http://www.micromet-inc.com